Most Read

The condition has an estimated prevalence of 25,000 patients in the US and an annual incidence of one to three new cases per 100,000 people. CK0804 is an

The approval applies to patients whose disease is metastatic or locally advanced, or where surgery may cause morbidity, and who have progressed on prior therapies or lack satisfactory

The first-in-class, subcutaneously administered hepcidin mimetic peptide, rusfertide is intended to regulate iron homeostasis and red blood cell production to help manage haematocrit levels in PV patients. The

The approval provides a new treatment option for this rare condition, which is linked to extremely elevated triglyceride levels and an increased risk of acute, recurrent pancreatitis. Redemplo

The partnership combines Insilico’s AI drug discovery platforms with Servier’s expertise in cancer drug development, aiming to address challenging targets in the oncology field. Under the agreement, Insilico

The company has assumed commercial rights for Byooviz from Biogen, and the product will now be available as a Samsung Bioepis brand across several European countries as part

The approval is based on the Phase I/II GO29781 clinical study, with full approval contingent upon further confirmatory trials. Lunsumio VELO’s SC injection requires around one minute, compared

The move will give Samsung Biologics its first manufacturing site in the country as part of its long-term commitment to the market. The Rockville, Maryland facility is located

In patients suffering with oHCM, myosin inhibition with MYQORZO, which is an allosteric and reversible inhibitor of cardiac myosin motor activity, lowers left ventricular outflow tract (LVOT) obstruction